Drug Profile
Research programme: anticancer antibody therapeutics - Adimab/Merrimack Pharmaceuticals
Alternative Names: MM-131; Signaling inhibitorsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Adimab
- Developer Adimab; Merrimack Pharmaceuticals
- Class Antibodies; Bispecific antibodies
- Mechanism of Action Epithelial cell adhesion molecule inhibitors; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 08 Jan 2017 Research programme: anticancer antibody therapeutics - Adimab/Merrimack Pharmaceuticals is available for licensing as of 08 Jan 2017. www.merrimack.com
- 10 Dec 2014 Preclinical development is ongoing USA